JFA
NAVB

JNBA Financial Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

JNBA Financial Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25
Closed – – 1571
2016
Q3 		$0 Buy
+25
New +$316 ﹤0.01% 1709

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JNBA Financial Advisors's NAVB Position: Q4 2016 in Review

JNBA Financial Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2016, closing a stake of 25 shares.

JNBA Financial Advisors first reported a position in NAVB in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q4 2016.

  • JNBA Financial Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
  • JNBA Financial Advisors sold 25 Navidea Biopharmaceuticals Inc. shares in Q4 2016.
  • JNBA Financial Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2016 and held it in 1 quarter.
  • JNBA Financial Advisors's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q3 2016.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2016.

Based on JNBA Financial Advisors's 13F filing for Q4 2016, filed 3 Feb 2017.